Table 1 Patient Characteristics of the cohorts from 2019 and 2020.
Treatment year | P | ||||
|---|---|---|---|---|---|
Total (n = 251) | 2019 (n = 132) | 2020 (n = 119) | |||
Age in years, mean ± SD | 61.3 ± 12.8 | 61.0 ± 11.8 | 61.6 ± 13.3 | .732 | |
Median (range) | 61 (18–88) | 61 (18–88) | 63 (21–87) | ||
Gender | Female | 105 | 52 | 53 | .409 |
41.8% | 39.4% | 44.5% | |||
Male | 146 | 80 | 66 | ||
58.2% | 60.6% | 55.5% | |||
Entity | Anaplastic astrocytoma | 9 | 1 | 8 | .260 |
3.6% | 0.8% | 6.7% | |||
Anaplastic oligodendroglioma | 17 | 9 | 8 | ||
6.8% | 6.8% | 6.7% | |||
Glioblastoma | 217 | 118 | 99 | ||
86.4% | 89.4% | 83.2% | |||
Gliosarcoma | 2 | 1 | 1 | ||
0.8% | 0.8% | 0.8% | |||
Medulloblastoma | 2 | 1 | 1 | ||
0.8% | 0.8% | 0.8% | |||
Other | 4 | 2 | 2 | ||
1.6% | 1.5% | 1.6% | |||
WHO | 3 | 26 | 10 | 16 | .128 |
10.4% | 7.6% | 13.4% | |||
4 | 225 | 122 | 103 | ||
89.6% | 92.4% | 86.6% | |||
IDH mutation | Mutated | 28 | 13 | 15 | .489 |
11.2% | 9.8% | 12.6% | |||
Wildtype | 221 | 118 | 103 | ||
88.0% | 89.4% | 86.6% | |||
Unknown | 2 | 1 | 1 | ||
0.8% | 0.8% | 0.8% | |||
MGMT promotor | Negative | 123 | 65 | 58 | .537 |
49.0% | 49.2% | 48.7% | |||
Positive | 124 | 66 | 58 | ||
49.4% | 50.0% | 48.7% | |||
Unknown | 4 | 1 | 3 | ||
1.6% | 0.8% | 2.6% | |||
1p19q codeletion | Co-deleted | 17 | 8 | 9 | .455 |
6.8% | 6.1% | 7.6% | |||
Non-co-deleted | 61 | 28 | 33 | ||
24.3% | 21.2% | 27.7% | |||
Unknown | 173 | 96 | 77 | ||
68.9% | 72.7% | 64.7% | |||
